{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:20:45Z","timestamp":1781796045307,"version":"3.54.5"},"reference-count":83,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.bbmt.2016.04.018","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T06:43:58Z","timestamp":1461998638000},"page":"1348-1356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Celalettin","family":"Ustun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsiporah","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif Selim","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rogosheske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Besien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hagglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.04.018_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000048180","article-title":"Histopathological and immunohistochemical aspects of mastocytosis","volume":"127","author":"Horny","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.04.018_bib3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.04.018_bib4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib5","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.04.018_bib7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2015-06-649525","article-title":"Cladribine for mastocytosis: benefits and risks","volume":"126","author":"Akin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/ejh.12544","article-title":"Current treatment options in patients with mastocytosis: status in 2015 and future perspectives","volume":"94","author":"Arock","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib10","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.04.018_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.04.018_bib13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.04.018_bib14","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.04.018_bib15","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib16","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib17","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ajh.23942","article-title":"Bosutinib, a Lyn\/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis","volume":"90","author":"Randall","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V","volume":"33","author":"Ustun","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.04.018_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.636.636","article-title":"Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial","volume":"124","author":"Gotlib","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A\u00a0pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.018_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.bmt.1704098","article-title":"Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation","volume":"32","author":"Chen","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.018_bib22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/bmt.2012.198","article-title":"Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological non-mast cell lineage disease after allogeneic transplantation","volume":"48","author":"Gromke","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.018_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","article-title":"Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation","volume":"34","author":"Spyridonidis","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.018_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.leukres.2006.03.006","article-title":"Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone","volume":"31","author":"Pullarkat","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.04.018_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3","article-title":"Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases","volume":"57","author":"Przepiorka","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib26","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V84.9.2954.2954","article-title":"Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation","volume":"84","author":"Fodinger","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib27","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib29","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.018_bib30","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.exphem.2007.08.016","article-title":"The origin of neoplastic mast cells in systemic mastocytosis with AML1\/ETO-positive acute myeloid leukemia","volume":"35","author":"Nagai","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MOH.0000000000000124","article-title":"Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia","volume":"22","author":"Ustun","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.molonc.2010.04.008","article-title":"High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V","volume":"4","author":"Fritsche-Polanz","year":"2010","journal-title":"Mol Oncol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2014.09.010","article-title":"Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features","volume":"39","author":"Valent","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.04.018_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: state of the art","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"key":"10.1016\/j.bbmt.2016.04.018_bib36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bbmt.2016.04.018_bib38","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.bbmt.2016.04.018_bib39","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"19 Pt 1","key":"10.1016\/j.bbmt.2016.04.018_bib40","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1158\/1078-0432.CCR-05-1064","article-title":"Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation","volume":"11","author":"Sperr","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.04.018_bib41","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ajh.21713","article-title":"Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge","volume":"85","author":"Arredondo","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood.V92.2.394","article-title":"Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase","volume":"92","author":"Morton","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib43","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib44","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib45","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.04.018_bib46","first-page":"CD010189","article-title":"Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults","volume":"4","author":"Holtick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bbmt.2016.04.018_bib47","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.bbmt.2009.06.016","article-title":"Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse","volume":"15","author":"Weisdorf","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.018_bib48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib49","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","article-title":"Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells","volume":"108","author":"Gabillot-Carre","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib50","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","article-title":"Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation","volume":"112","author":"Cutler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000329218","article-title":"Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience","volume":"157","author":"Wimazal","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11882-009-0080-8","article-title":"Anaphylaxis and mast cell disease: what is the risk?","volume":"10","author":"Akin","year":"2010","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.bbmt.2016.04.018_bib53","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.bbmt.2016.04.018_bib54","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/bmt.2014.116","article-title":"Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation","volume":"49","author":"Bejanyan","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.018_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","article-title":"Bone involvement and osteoporosis in mastocytosis","volume":"34","author":"Rossini","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.bbmt.2016.04.018_bib56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2008.070061","volume":"10","author":"Sotlar","year":"2008","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.bbmt.2016.04.018_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7863\/jum.1997.16.3.223","article-title":"Liver infiltration in systemic mastocytosis: ultrasonographic findings","volume":"16","author":"Bastart","year":"1997","journal-title":"J\u00a0Ultrasound Med"},{"key":"10.1016\/j.bbmt.2016.04.018_bib58","doi-asserted-by":"crossref","first-page":"1127.e1121","DOI":"10.1016\/j.amjmed.2014.06.015","article-title":"Zoledronic acid in osteoporosis secondary to mastocytosis","volume":"127","author":"Rossini","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2016.04.018_bib59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4274\/tjh.2013.0170","article-title":"Osteoporosis and osteopathy markers in patients with mastocytosis","volume":"32","author":"Alpay Kanitez","year":"2015","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/ejh.12720","article-title":"Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease","volume":"96","author":"Ustun","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib61","first-page":"76","article-title":"Systemic mastocytosis with portal hypertension. Autopsy findings and ultrastructural study of the liver","volume":"109","author":"Ghandur-Mnaymneh","year":"1985","journal-title":"Arch Pathol Lab Med"},{"issue":"3 Suppl","key":"10.1016\/j.bbmt.2016.04.018_bib62","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1111\/1523-1747.ep12469022","article-title":"The liver, spleen, and lymph nodes in mastocytosis","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib63","first-page":"5","article-title":"Mast cells and idiopathic lung fibrosis","volume":"21","author":"Fortoul","year":"1990","journal-title":"Arch Invest Med (Mex)"},{"issue":"4 Pt 1","key":"10.1016\/j.bbmt.2016.04.018_bib64","first-page":"1163","article-title":"Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases","volume":"22","author":"Mican","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2016.04.018_bib65","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.14309\/00000434-201010001-00810","article-title":"Hepatic manifestations of systemic mastocytosis (SM)","volume":"105","author":"Grigg","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib66","doi-asserted-by":"crossref","first-page":"728172","DOI":"10.1155\/2012\/728172","article-title":"Systemic mastocytosis: a rare case of increased liver stiffness","volume":"2012","author":"Adolf","year":"2012","journal-title":"Case Reports Hepatol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib67","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1165\/rcmb.2008-0044OC","article-title":"Pulmonary mastocytosis and enhanced lung inflammation in mice heterozygous null for the Foxf1 gene","volume":"39","author":"Kalin","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib68","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.13215","article-title":"How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation","volume":"168","author":"Carreras","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib69","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood-2016-01-690669","article-title":"Resolution of osteosclerosis after alloHCT in systemic mastocytosis","volume":"127","author":"Ustun","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.6.6","volume":"126","author":"Stone","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib71","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","article-title":"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers","volume":"72","author":"Dutreix","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib72","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2007.02.007","article-title":"Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels","volume":"123","author":"Akin","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib73","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib74","doi-asserted-by":"crossref","first-page":"e76116","DOI":"10.1371\/journal.pone.0076116","article-title":"Serum tryptase monitoring in indolent systemic mastocytosis: association with\u00a0disease features and patient outcome","volume":"8","author":"Matito","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2016.04.018_bib75","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2362.2009.02184.x","article-title":"Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology","volume":"39","author":"Sperr","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bbmt.2016.04.018_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib77","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.bbmt.2016.04.018_bib78","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1034\/j.1399-3003.2000.15.32.x","article-title":"Pulmonary manifestation of systemic mast cell disease","volume":"15","author":"Schmidt","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bbmt.2016.04.018_bib79","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1259\/0007-1285-60-716-765","article-title":"Radiological features of systemic mast-cell disease","volume":"60","author":"Huang","year":"1987","journal-title":"Br J Radiol"},{"key":"10.1016\/j.bbmt.2016.04.018_bib80","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.018_bib81","doi-asserted-by":"crossref","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2016.04.018_bib82","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2013.095133","article-title":"SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes","volume":"99","author":"Hanssens","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.04.018_bib83","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116300374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116300374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:54:56Z","timestamp":1761058496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116300374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1083879116300374"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.018","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}